Biologics in the management of psoriasis
نویسندگان
چکیده
Psoriasis is a chronic inflammatory systemic disease for which there exist topical, ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Alefacept and efalizumab target T lymphocytes, are effective in the treatment of psoriasis, but are not approved for psoriatic arthritis. Finally, ustekinumab and ABT-874 target interleukin-12 and interleukin-23, and they have demonstrated efficacy in the treatment of psoriasis. The objective of this review is to present efficacy and safety data from randomized controlled trials of the biologic agents in the treatment of psoriasis.
منابع مشابه
Estimation of direct and indirect costs of one year treatment for psoriasis outpatients in Iran: a study in Razi Hospital in 2017-2018
Background and Aim: Psoriasis is a systemic and non-transmissible chronic inflammatory autoimmune skin disease that about 2-3% of Iranians suffer from it. Cost of management and budgeting and planning for the treatment of patients with psoriasis requires accurate information. The present study estimates the direct and indirect costs for one-year treatment of patients admitted in Razi Dermatolog...
متن کاملNail psoriasis.
Nail psoriasis affects nearly 80% of patients with plaque psoriasis and is even more prevalent in patients with psoriatic arthritis. Nail psoriasis is not simply a cosmetic problem but one that effects the structure and function of the nail, resulting in negative psychological effects. The first level in management of nail psoriasis is patient education. The hierarchy of nail psoriasis therapy ...
متن کاملNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
The development of effective and well-tolerated biologic therapies has advanced the management of psoriasis by enabling clinicians to treat underlying disease mechanisms. Biologics approved for the treatment of moderate-to-severe psoriasis include three tumor necrosis factor alpha inhibitors and an interleukin-12/interleukin-23 inhibitor. The establishment of the immunological basis of psoriasi...
متن کامل[Guidelines on the use of methotrexate in psoriasis].
Psoriasis, a chronic multifactorial inflammatory disease that develops in genetically predisposed individuals, affects approximately 1.5% of the Spanish population. This disease has a negative impact on patients' quality of life, and long-term therapy is often required to control the symptoms. In addition to the classical systemic treatments (methotrexate, acitretin, cyclosporine, and ultraviol...
متن کاملIdentifying training and informational components to develop a psoriasis self- management application
Background: Psoriasis is a complex disease with lifelong emotional and social consequences for affected patients. It also reduces the patients’ quality of life and requires a long-term management. Therefore, in addition to appropriate treatment of the disease, self-management strategies to improve patient health and quality of life are essential. On the other hand, smartphone-based applic...
متن کامل